Sun Pharma partners with AstraZeneca India over Type II diabetes medicine

Under the agreement, Sun Pharma will promote and distribute dapagliflozin under the brand name ‘Oxra’

Sun Pharma and AstraZeneca Pharma India announced a partnership for the distribution of dapagliflozin, an innovative Type II diabetes medicine, in India. Dapagliflozin is AstraZeneca India’s leading diabetes medicine.

Under the agreement, Sun Pharma will promote and distribute dapagliflozin under the brand name ‘Oxra’. AstraZeneca India markets dapagliflozin under the brand name Forxiga and under the terms of the agreement, both companies will promote, market and distribute dapagliflozin in India under different brand names. AstraZeneca will retain the intellectual property rights to dapagliflozin.

Sun Pharma will also gain the rights to promote and distribute the combination of dapagliflozin with metformin under the brand name ‘Oxramet’, following regulatory approval. AstraZeneca India is currently seeking approval from the Drug Controller General of India for the combination of dapagliflozin with metformin.